Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France

Table 2 Summary of base case results and subgroup analyses

	Bevacizumab plus paclitaxel	Paclitaxel alone	Difference
Life years gained
Overall population	2.993	2.272	0.721
HR+	3.504	2.495	1.009
Triple negative	1.971	1.510	0.461
QALYs gained
Overall population	2.006	1.523	0.483
HR+	2.327	1.674	0.652
Triple negative	1.341	1.015	0.327
Total lifetime costs, EUR
Overall population	54,315	26,925	27,390
HR+	61,805	29,350	32,454
Triple negative	40,246	18,391	21,856
ICER, EUR per QALY gained
Overall population		56,721
HR+		49,749
Triple negative		66,874
ICER, EUR per life year gaine
Overall population		38,003
HR+		32,171
Triple negative		47,447

HR+ hormone receptor positive, ICER incremental cost-effectiveness ratio, QALYs quality adjusted life years

ISSN: 1471-2407